menu toggle

In conversation with TrakCel: Why successful partnerships can help accelerate advanced therapies

By AmerisourceBergen

Earlier this year, AmerisourceBergen and TrakCel participated to one of the most attended and immersive events for the cell and gene therapy sector: Phacilitate's Advanced Therapies Week.


Being the destination for anyone developing, investing or interested in cell and gene therapies, this conference was the perfect place to share our expertise around the keys to accelerate access for cell and gene therapies, and deliver complete visibility throughout the patient journey.

Watch Vice President, Adherence and Analytics, Jeff Buck, as he joined TrakCel’s cofounder and Vice President of Scientific Affairs and Business Development, Dr. Matthew Lakelin, to discuss how successful partnerships can help increase advanced therapies’ connectivity and speed to market.

Cell and Gene therapy alternative reimbursement models

Interview: Increasing advanced therapies connectivity and speed to market through partnership

Cell and Gene therapy alternative reimbursement models
Cell and Gene therapy alternative reimbursement models

Learn more about AmerisourceBergen and TrakCel’s integrated platform

Topics:
Cell and gene therapy Commercialization Innovation

Related Content

Manufacturers

Podcast: Industry led product development in a rapidly changing CGT landscape

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2023
Autologous cell and gene therapies

Manufacturers

Evaluating alternative revolutionary reimbursement models to craft a sustainable business model for cell and gene therapies

A photo of David Senior wearing a dark gray suit, white collared shirt, and dark blue tie with a diamond pattern
David Senior
AmerisourceBergen
October 2022
Reimbursement models for CGT

Manufacturers

Alternate payer engagement models are changing the landscape

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2022
Cell and gene therapy Alternate payer engagement models